Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers

Thomas F. Newton, Malcolm S. Reid, Richard De La Garza, James J. Mahoney, Antonio Abad, Rany Condos, Joseph Palamar, Perry N. Halkitis, Jurji Mojisak, Ann Anderson, Shou Hua Li, Ahmed Elkashef

Research output: Contribution to journalArticle

Abstract

A variety of neuropharmacological strategies are being pursued in the search for an effective treatment for methamphetamine (Meth) addiction. In this study, we investigated the safety and potential efficacy of aripiprazole, an antipsychotic agent acting on both dopamine and serotonin systems. We conducted a double-blind in-patient clinical pharmacology study to assess potential interactions between intravenous (i.v.) Meth (15 mg and 30 mg) and oral aripiprazole (15 mg). In addition, the effects of aripiprazole treatment on abstinence-related craving and cue-induced craving were evaluated. Participants included non-treatment-seeking, Meth-dependent patients (n=16), aged 18-45 yr, currently using Meth. Following baseline Meth dosing (15 mg and 30 mg), participants received 2 wk treatment with aripiprazole (n=8) or placebo (n=8). Participants then completed cue exposure sessions using neutral and Meth-related cues. Meth dosing (15 mg and 30 mg) was then repeated. Aripiprazole treatment had no effect on cue-induced Meth craving, or on daily baseline craving assessed over the course of medication treatment, although aripiprazole treatment was associated with increased craving independent of Meth dosing. Aripiprazole treatment was associated with significantly higher ratings on Addiction Research Center Inventory (ARCI) subscales reflecting euphoria and amphetamine-like effects following Meth dosing. Aripiprazole treatment was also associated with significant reductions in ratings of 'bad effects' and reductions on the ARCI subscale for sedation effects following Meth dosing. Aripiprazole treatment reduced the increase in systolic blood pressure following Meth dosing, but had no other effects on cardiovascular responses to Meth. Aripiprazole treatment did not alter the pharmacokinetics of Meth. These findings indicate that aripiprazole treatment appears to be safe in volunteers with Meth dependence, although the finding that aripiprazole increased some of the rewarding and stimulatory effects produced by acute Meth suggests that 15 mg aripiprazole is unlikely to be efficacious for the treatment of Meth dependence. Further research with lower doses of aripiprazole, possibly using study designs aimed at evaluating efficacy for relapse prevention, are needed before ruling out aripiprazole as a treatment for Meth dependence.

Original languageEnglish (US)
Pages (from-to)1037-1045
Number of pages9
JournalInternational Journal of Neuropsychopharmacology
Volume11
Issue number8
DOIs
StatePublished - Dec 2008

Fingerprint

Methamphetamine
Volunteers
Cues
Therapeutics
Aripiprazole
Research
Blood Pressure
Equipment and Supplies
Clinical Pharmacology
Amphetamine

Keywords

  • Aripiprazole
  • Methamphetamine
  • Subjective effects

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health

Cite this

Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. / Newton, Thomas F.; Reid, Malcolm S.; De La Garza, Richard; Mahoney, James J.; Abad, Antonio; Condos, Rany; Palamar, Joseph; Halkitis, Perry N.; Mojisak, Jurji; Anderson, Ann; Li, Shou Hua; Elkashef, Ahmed.

In: International Journal of Neuropsychopharmacology, Vol. 11, No. 8, 12.2008, p. 1037-1045.

Research output: Contribution to journalArticle

Newton, TF, Reid, MS, De La Garza, R, Mahoney, JJ, Abad, A, Condos, R, Palamar, J, Halkitis, PN, Mojisak, J, Anderson, A, Li, SH & Elkashef, A 2008, 'Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers', International Journal of Neuropsychopharmacology, vol. 11, no. 8, pp. 1037-1045. https://doi.org/10.1017/S1461145708009097
Newton, Thomas F. ; Reid, Malcolm S. ; De La Garza, Richard ; Mahoney, James J. ; Abad, Antonio ; Condos, Rany ; Palamar, Joseph ; Halkitis, Perry N. ; Mojisak, Jurji ; Anderson, Ann ; Li, Shou Hua ; Elkashef, Ahmed. / Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. In: International Journal of Neuropsychopharmacology. 2008 ; Vol. 11, No. 8. pp. 1037-1045.
@article{23089b248f8b448cab8c29186b3b50c7,
title = "Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers",
abstract = "A variety of neuropharmacological strategies are being pursued in the search for an effective treatment for methamphetamine (Meth) addiction. In this study, we investigated the safety and potential efficacy of aripiprazole, an antipsychotic agent acting on both dopamine and serotonin systems. We conducted a double-blind in-patient clinical pharmacology study to assess potential interactions between intravenous (i.v.) Meth (15 mg and 30 mg) and oral aripiprazole (15 mg). In addition, the effects of aripiprazole treatment on abstinence-related craving and cue-induced craving were evaluated. Participants included non-treatment-seeking, Meth-dependent patients (n=16), aged 18-45 yr, currently using Meth. Following baseline Meth dosing (15 mg and 30 mg), participants received 2 wk treatment with aripiprazole (n=8) or placebo (n=8). Participants then completed cue exposure sessions using neutral and Meth-related cues. Meth dosing (15 mg and 30 mg) was then repeated. Aripiprazole treatment had no effect on cue-induced Meth craving, or on daily baseline craving assessed over the course of medication treatment, although aripiprazole treatment was associated with increased craving independent of Meth dosing. Aripiprazole treatment was associated with significantly higher ratings on Addiction Research Center Inventory (ARCI) subscales reflecting euphoria and amphetamine-like effects following Meth dosing. Aripiprazole treatment was also associated with significant reductions in ratings of 'bad effects' and reductions on the ARCI subscale for sedation effects following Meth dosing. Aripiprazole treatment reduced the increase in systolic blood pressure following Meth dosing, but had no other effects on cardiovascular responses to Meth. Aripiprazole treatment did not alter the pharmacokinetics of Meth. These findings indicate that aripiprazole treatment appears to be safe in volunteers with Meth dependence, although the finding that aripiprazole increased some of the rewarding and stimulatory effects produced by acute Meth suggests that 15 mg aripiprazole is unlikely to be efficacious for the treatment of Meth dependence. Further research with lower doses of aripiprazole, possibly using study designs aimed at evaluating efficacy for relapse prevention, are needed before ruling out aripiprazole as a treatment for Meth dependence.",
keywords = "Aripiprazole, Methamphetamine, Subjective effects",
author = "Newton, {Thomas F.} and Reid, {Malcolm S.} and {De La Garza}, Richard and Mahoney, {James J.} and Antonio Abad and Rany Condos and Joseph Palamar and Halkitis, {Perry N.} and Jurji Mojisak and Ann Anderson and Li, {Shou Hua} and Ahmed Elkashef",
year = "2008",
month = "12",
doi = "10.1017/S1461145708009097",
language = "English (US)",
volume = "11",
pages = "1037--1045",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "8",

}

TY - JOUR

T1 - Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers

AU - Newton, Thomas F.

AU - Reid, Malcolm S.

AU - De La Garza, Richard

AU - Mahoney, James J.

AU - Abad, Antonio

AU - Condos, Rany

AU - Palamar, Joseph

AU - Halkitis, Perry N.

AU - Mojisak, Jurji

AU - Anderson, Ann

AU - Li, Shou Hua

AU - Elkashef, Ahmed

PY - 2008/12

Y1 - 2008/12

N2 - A variety of neuropharmacological strategies are being pursued in the search for an effective treatment for methamphetamine (Meth) addiction. In this study, we investigated the safety and potential efficacy of aripiprazole, an antipsychotic agent acting on both dopamine and serotonin systems. We conducted a double-blind in-patient clinical pharmacology study to assess potential interactions between intravenous (i.v.) Meth (15 mg and 30 mg) and oral aripiprazole (15 mg). In addition, the effects of aripiprazole treatment on abstinence-related craving and cue-induced craving were evaluated. Participants included non-treatment-seeking, Meth-dependent patients (n=16), aged 18-45 yr, currently using Meth. Following baseline Meth dosing (15 mg and 30 mg), participants received 2 wk treatment with aripiprazole (n=8) or placebo (n=8). Participants then completed cue exposure sessions using neutral and Meth-related cues. Meth dosing (15 mg and 30 mg) was then repeated. Aripiprazole treatment had no effect on cue-induced Meth craving, or on daily baseline craving assessed over the course of medication treatment, although aripiprazole treatment was associated with increased craving independent of Meth dosing. Aripiprazole treatment was associated with significantly higher ratings on Addiction Research Center Inventory (ARCI) subscales reflecting euphoria and amphetamine-like effects following Meth dosing. Aripiprazole treatment was also associated with significant reductions in ratings of 'bad effects' and reductions on the ARCI subscale for sedation effects following Meth dosing. Aripiprazole treatment reduced the increase in systolic blood pressure following Meth dosing, but had no other effects on cardiovascular responses to Meth. Aripiprazole treatment did not alter the pharmacokinetics of Meth. These findings indicate that aripiprazole treatment appears to be safe in volunteers with Meth dependence, although the finding that aripiprazole increased some of the rewarding and stimulatory effects produced by acute Meth suggests that 15 mg aripiprazole is unlikely to be efficacious for the treatment of Meth dependence. Further research with lower doses of aripiprazole, possibly using study designs aimed at evaluating efficacy for relapse prevention, are needed before ruling out aripiprazole as a treatment for Meth dependence.

AB - A variety of neuropharmacological strategies are being pursued in the search for an effective treatment for methamphetamine (Meth) addiction. In this study, we investigated the safety and potential efficacy of aripiprazole, an antipsychotic agent acting on both dopamine and serotonin systems. We conducted a double-blind in-patient clinical pharmacology study to assess potential interactions between intravenous (i.v.) Meth (15 mg and 30 mg) and oral aripiprazole (15 mg). In addition, the effects of aripiprazole treatment on abstinence-related craving and cue-induced craving were evaluated. Participants included non-treatment-seeking, Meth-dependent patients (n=16), aged 18-45 yr, currently using Meth. Following baseline Meth dosing (15 mg and 30 mg), participants received 2 wk treatment with aripiprazole (n=8) or placebo (n=8). Participants then completed cue exposure sessions using neutral and Meth-related cues. Meth dosing (15 mg and 30 mg) was then repeated. Aripiprazole treatment had no effect on cue-induced Meth craving, or on daily baseline craving assessed over the course of medication treatment, although aripiprazole treatment was associated with increased craving independent of Meth dosing. Aripiprazole treatment was associated with significantly higher ratings on Addiction Research Center Inventory (ARCI) subscales reflecting euphoria and amphetamine-like effects following Meth dosing. Aripiprazole treatment was also associated with significant reductions in ratings of 'bad effects' and reductions on the ARCI subscale for sedation effects following Meth dosing. Aripiprazole treatment reduced the increase in systolic blood pressure following Meth dosing, but had no other effects on cardiovascular responses to Meth. Aripiprazole treatment did not alter the pharmacokinetics of Meth. These findings indicate that aripiprazole treatment appears to be safe in volunteers with Meth dependence, although the finding that aripiprazole increased some of the rewarding and stimulatory effects produced by acute Meth suggests that 15 mg aripiprazole is unlikely to be efficacious for the treatment of Meth dependence. Further research with lower doses of aripiprazole, possibly using study designs aimed at evaluating efficacy for relapse prevention, are needed before ruling out aripiprazole as a treatment for Meth dependence.

KW - Aripiprazole

KW - Methamphetamine

KW - Subjective effects

UR - http://www.scopus.com/inward/record.url?scp=55549100989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549100989&partnerID=8YFLogxK

U2 - 10.1017/S1461145708009097

DO - 10.1017/S1461145708009097

M3 - Article

VL - 11

SP - 1037

EP - 1045

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 8

ER -